Cefadroxil Bacterial Coverage
Cefadroxil is a first-generation oral cephalosporin that covers methicillin-susceptible Staphylococcus aureus (MSSA), beta-hemolytic streptococci (including Streptococcus pyogenes), Streptococcus pneumoniae, and select Gram-negative organisms including E. coli, Proteus mirabilis, and Klebsiella species. 1
Gram-Positive Coverage
Cefadroxil demonstrates robust activity against:
- Staphylococcus aureus (penicillinase-producing strains, but NOT methicillin-resistant strains)
- Beta-hemolytic streptococci (including Group A Streptococcus pyogenes)
- Streptococcus pneumoniae
- Moraxella (Branhamella) catarrhalis 1
The drug is specifically indicated for pharyngitis/tonsillitis caused by Group A beta-hemolytic streptococci and skin/soft tissue infections caused by staphylococci and/or streptococci 1. In IDSA guidelines for skin and soft tissue infections, cephalexin (a closely related first-generation cephalosporin) is listed as an appropriate oral agent for MSSA infections 2, and cefadroxil shares equivalent in vitro activity with cephalexin against MSSA (both with MIC50 of 2 μg/mL and MIC90 of 4 μg/mL) 3.
Gram-Negative Coverage
Cefadroxil covers a limited spectrum of Gram-negative organisms:
- Escherichia coli
- Proteus mirabilis
- Klebsiella species 1
These organisms are the primary targets for urinary tract infections, which is a key FDA-approved indication 1.
Critical Gaps in Coverage
Cefadroxil does NOT cover:
- Methicillin-resistant Staphylococcus aureus (MRSA) - requires alternative agents like vancomycin, linezolid, or clindamycin 2
- Enterococcus faecalis and Enterococcus faecium - most strains are resistant 1
- Enterobacter species
- Morganella morganii and Proteus vulgaris
- Pseudomonas species
- Acinetobacter calcoaceticus 1
Clinical Context and Pitfalls
Common pitfall: Assuming all staphylococcal coverage includes MRSA. Cefadroxil only covers methicillin-susceptible strains. In areas with high MRSA prevalence or in patients with risk factors for MRSA (prior MRSA infection, recent hospitalization, injection drug use), empiric cefadroxil is inappropriate for skin infections 2.
Important consideration for UTIs: While cefadroxil covers common uropathogens (E. coli, Proteus, Klebsiella), it does NOT cover extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae 4. Culture and susceptibility testing should guide therapy, particularly in complicated cases or treatment failures 1.
The drug achieves excellent urinary concentrations (approximately 1800 mcg/mL following a 500-mg dose) that remain above the MIC of susceptible urinary pathogens for 20-22 hours 1, making it effective for uncomplicated UTIs caused by susceptible organisms.
Dosing advantage: Cefadroxil's longer half-life compared to cephalexin allows for twice-daily dosing rather than four times daily, potentially improving adherence 5, 3.